Volume 28, Supplement—December 2022
SUPPLEMENT ISSUE
Clinical
CDC’s COVID-19 International Vaccine Implementation and Evaluation Program and Lessons from Earlier Vaccine Introductions
Table 1
CDC priority technical areas to support global COVID-19 vaccine implementation through the COVID-19 International Vaccine Implementation and Evaluation (CIVIE) program
Technical area | Examples of CDC-supported activities |
---|---|
Vaccine policy development | Assist with data review to inform prioritization and planning for vaccination of risk groups |
Support and strengthen national-level decision making and National Immunization Technical Advisory Groups via trainings and workshops |
|
Program planning | Support microplanning for populations targeted for vaccination |
Help design logistical and distribution plans for different vaccination scenarios or products |
|
Vaccine confidence and demand | Develop and provide standard tools for country-level adaptation to collect data on behavioral and social barriers to vaccine uptake |
Provide support to assess and manage the effect of infodemics* on vaccine confidence and uptake | |
Provide messaging and communications technical assistance, materials, and tools |
|
Data management and use |
Provide technical assistance to rapidly assess, develop, implement, and monitor data management systems and tools used for COVID-19 vaccine introduction and safety monitoring |
Workforce development | Conduct rapid performance assessments to understand workforce-related barriers and facilitators to delivering COVID-19 vaccine |
Provide evidence-based tools and techniques for improving supervision |
|
Vaccine safety | Strengthen passive or enhanced surveillance for adverse events following immunization |
Use active surveillance or special studies to address key questions on COVID-19 vaccine safety | |
Ensure preparedness to respond to safety events through vaccine-related event response planning |
|
Evaluation | Support post-introduction evaluations using standard WHO tools |
Conduct targeted evaluations of vaccine effectiveness to address key global evidence gaps |
*Infodemic, “overabundance of information during a disease outbreak” (17).
References
- UK Coronavirus Dashboard. Coronavirus (COVID-19) in the UK—vaccinations. 2021 [cited 2021 Sep 2]. https://coronavirus.data.gov.uk/details/vaccinations
- Painter EM, Ussery EN, Patel A, Hughes MM, Zell ER, Moulia DL, et al. Demographic characteristics of persons vaccinated during the first month of the COVID-19 vaccination program—United States, December 14, 2020–January 14, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:174–7. DOIPubMedGoogle Scholar
- World Health Organization. Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing: interim guidance, 8 January 2021. 2021 [cited 2021 Sep 2]. https://apps.who.int/iris/handle/10665/338484
- World Health Organization. WHO coronavirus (COVID-19) dashboard. 2022 [cited 2022 Apr 4]. https://covid19.who.int
- World Health Organization. Coronavirus disease (COVID-19). WHO—prequalification of medical products. 2022 [cited 2022 Apr 4]. https://extranet.who.int/pqweb/vaccines/covid-19-vaccines
- World Health Organization. The Access to COVID-19 Tools (ACT) accelerator. 2020 [cited 2021 Sep 23]. https://www.who.int/initiatives/act-accelerator
- World Health Organization. COVAX. 2021 [cited 2021 Oct 12]. https://www.who.int/initiatives/act-accelerator/covax
- Berkley S. COVAX explained. 2020 [cited 2021 Sep 23]. https://www.gavi.org/vaccineswork/covax-explained
- US Agency for International Development. USAID’s COVID-19 response. 2021 [cited 2021 Aug 26]. https://www.usaid.gov/coronavirus
- The White House. Fact sheet: President Biden’s global COVID-19 summit: ending the pandemic and building back better. 2021 [cited 2021 Sep 23]. https://www.whitehouse.gov/briefing-room/statements-releases/2021/09/22/fact-sheet-president-bidens-global-covid-19-summit-ending-the-pandemic-and-building-back-better
- Centers for Disease Control and Prevention. CDC strategy for global response to COVID-19 (2020–2023). 2020 [cited 2021 Sep 23]. https://www.cdc.gov/coronavirus/2019-ncov/global-covid-19/global-response-strategy.html
- World Health Organization. Immunization agenda 2030. 2021 [cited 2021 Jun 18]. http://www.immunizationagenda2030.org
- World Health Organization. Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines: interim guidance. 2021 [cited 2022 Apr 4]. https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccine-deployment-2021.1-eng
- Centers for Disease Control and Prevention. CDC Global Immunization Strategic Framework 2021–2030. 2021 [cited 2022 April 4]. https://www.cdc.gov/globalhealth/immunization/framework/index.html
- UNICEF. COVAX information centre. 2021 [cited 2021 Sep 23]. https://www.unicef.org/coronavirus/covax
- Centers for Disease Control and Prevention. CDC accelerates global COVID-19 vaccinations through Global Vax. 2022 [cited 2022 Apr 5]. https://www.cdc.gov/coronavirus/2019-ncov/downloads/COVID-19-GLOBAL-VAX-508.pdf
- Centers for Disease Control and Prevention. CDC begins third year of COVID-19 response with goal of increasing global vaccination. 2022 [cited 2022 Apr 10]. https://www.cdc.gov/globalhealth/stories/2022/CDC-Begins-Third-Year-COVID19-Response.html
- World Health Organization. Infodemic. 2021 [cited 2022 Apr 4]. https://www.who.int/health-topics/infodemic
- Williams SR, Driscoll AJ, LeBuhn HM, Chen WH, Neuzil KM, Ortiz JR. National routine adult immunisation programmes among World Health Organization Member States: an assessment of health systems to deploy COVID-19 vaccines. Euro Surveill. 2021;26:
2001195 . DOIPubMedGoogle Scholar - World Health Organization. WHO SAGE roadmap for prioritizing the use of COVID-19 vaccines in the context of limited supply: an approach to inform planning and subsequent recommendations based upon epidemiologic setting and vaccine supply scenarios, 13 November 2020, version 1.1. 2020 [cited 2021 Sep 23]. https://apps.who.int/iris/handle/10665/341448
- Tate J, Aguado T, Belie J, Holt D, Karafillakis E, Larson HJ, et al. The life-course approach to vaccination: Harnessing the benefits of vaccination throughout life. Vaccine. 2019;37:6581–3. DOIPubMedGoogle Scholar
- Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med. 2016;374:1647–60. DOIPubMedGoogle Scholar
- Kennedy SB, Neaton JD, Lane HC, Kieh MW, Massaquoi MB, Touchette NA, et al. Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges. Clin Trials. 2016;13:49–56. DOIPubMedGoogle Scholar
- Henao-Restrepo AM, Preziosi M-P, Wood D, Moorthy V, Kieny MP; WHO Ebola Research, Development Team. On a path to accelerate access to Ebola vaccines: The WHO’s research and development efforts during the 2014-2016 Ebola epidemic in West Africa. Curr Opin Virol. 2016;17:138–44. DOIPubMedGoogle Scholar
- Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386:857–66. DOIPubMedGoogle Scholar
- Aruna A, Mbala P, Minikulu L, Mukadi D, Bulemfu D, Edidi F, et al.; CDC Ebola Response. Ebola Virus Disease Outbreak - Democratic Republic of the Congo, August 2018-November 2019. MMWR Morb Mortal Wkly Rep. 2019;68:1162–5. DOIPubMedGoogle Scholar
- Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017;389:505–18. DOIPubMedGoogle Scholar
- World Health Organization. Ebola virus disease, Democratic Republic of the Congo, external situation report 91. 2020. [cited 2022 Apr 5]. https://apps.who.int/iris/handle/10665/331967
- WHO. Meeting of the Strategic Advisory Group of Experts on Immunization, 22–24 March 2021: conclusions and recommendations. Wkly Epidemiol Rec. 2021;96:197–216 https://apps.who.int/iris/bitstream/handle/10665/341623/WER9622-eng-fre.pdf.
- Coltart CE, Johnson AM, Whitty CJ. Role of healthcare workers in early epidemic spread of Ebola: policy implications of prophylactic compared to reactive vaccination policy in outbreak prevention and control. BMC Med. 2015;13:271. DOIPubMedGoogle Scholar
- Muzembo BA, Ntontolo NP, Ngatu NR, Khatiwada J, Ngombe KL, Numbi OL, et al. Local perspectives on Ebola during its tenth outbreak in DR Congo: A nationwide qualitative study. PLoS One. 2020;15:
e0241120 . DOIPubMedGoogle Scholar - Dada S, McKay G, Mateus A, Lees S. Lessons learned from engaging communities for Ebola vaccine trials in Sierra Leone: reciprocity, relatability, relationships and respect (the four R’s). BMC Public Health. 2019;19:1665. DOIPubMedGoogle Scholar
- Masumbuko Claude K, Underschultz J, Hawkes MT. Social resistance drives persistent transmission of Ebola virus disease in Eastern Democratic Republic of Congo: A mixed-methods study. PLoS One. 2019;14:
e0223104 . DOIPubMedGoogle Scholar - Carter S, Mobula L, Samaha H, Ahuka Mundeke S. Community engagement and vaccinations during the Ebola outbreak in Democratic Republic of Congo. Investing in Health 2020 [cited 2021 Jun 2]. https://blogs.worldbank.org/health/community-engagement-and-vaccinations-during-ebola-outbreak-democratic-republic-congo
- Social science and behavioural data compilation (No. 3), Ebola outbreak eastern DRC, February–May 2019. Social Science in Humanitarian Action [cited 2021 Jun 2]. https://opendocs.ids.ac.uk/opendocs/bitstream/handle/20.500.12413/14558/SSHAP_data_compilation_brief_No3_February_May_2019.pdf
- Palache A, Tsai T, Vasiliev Y, Abelin A, Hollingsworth R, Taylor B, et al. Global influenza vaccine distribution survey demonstrates urgency of implementation of objective 3 of WHO influenza strategy 2019–2030. Int Med Rev. 2020;6:1–27. DOIGoogle Scholar
- Porter RM, Goldin S, Lafond KE, Hedman L, Ungkuldee M, Kurzum J, et al. Does having a seasonal influenza program facilitate pandemic preparedness? An analysis of vaccine deployment during the 2009 pandemic. Vaccine. 2020;38:1152–9. DOIPubMedGoogle Scholar
- Ropero-Álvarez AM, El Omeiri N, Kurtis HJ, Danovaro-Holliday MC, Ruiz-Matus C. Influenza vaccination in the Americas: Progress and challenges after the 2009 A(H1N1) influenza pandemic. Hum Vaccin Immunother. 2016;12:2206–14. DOIPubMedGoogle Scholar
- Bresee JS, Lafond KE, McCarron M, Azziz-Baumgartner E, Chu SY, Ebama M, et al.; PIVI Partners Group. The partnership for influenza vaccine introduction (PIVI): Supporting influenza vaccine program development in low and middle-income countries through public-private partnerships. Vaccine. 2019;37:5089–95. DOIPubMedGoogle Scholar
- Bwaka A, Bita A, Lingani C, Fernandez K, Durupt A, Mwenda JM, et al. Status of the rollout of the meningococcal serogroup A conjugate vaccine in African meningitis belt countries in 2018. J Infect Dis. 2019;220(Suppl 4):S140–7. DOIPubMedGoogle Scholar
- World Health Organization. Meningococcal meningitis. 2021 [cited 2021 Sep 3]. https://www.who.int/news-room/fact-sheets/detail/meningococcal-meningitis
- Djingarey MH, Diomandé FV, Barry R, Kandolo D, Shirehwa F, Lingani C, et al. Introduction and rollout of a new group A meningococcal conjugate vaccine (PsA-TT) in African meningitis belt countries, 2010–2014. Clin Infect Dis. 2015;61(Suppl 5):S434–41. DOIPubMedGoogle Scholar
- Trotter CL, Lingani C, Fernandez K, Cooper LV, Bita A, Tevi-Benissan C, et al. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data. Lancet Infect Dis. 2017;17:867–72. DOIPubMedGoogle Scholar
- Nusair MB, Arabyat R, Khasawneh R, Al-Azzam S, Nusir AT, Alhayek MY. Assessment of the relationship between COVID-19 risk perception and vaccine acceptance: a cross-sectional study in Jordan. Hum Vaccin Immunother. 2022;18:
2017734 . DOIPubMedGoogle Scholar - Meningococcal A conjugate vaccine: updated guidance, February 2015. Wkly Epidemiol Rec. 2015;90:57–62.PubMedGoogle Scholar
- World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2020 global summary. 2020 [cited 2022 Apr 4]. https://apps.who.int/immunization_monitoring/globalsummary/schedules